Life Sciences

  • May 28, 2026

    Injury Law Roundup: Freight Brokers, Uber Lose Key Cases

    The U.S. Supreme Court's green light of negligent hiring claims against freight brokers in highway crash cases and an adverse verdict against Uber in the sexual assault multidistrict litigation lead Law360's Injury Law Roundup.

  • May 28, 2026

    Hospital Operator, Execs Ink $32M FCA Settlement With Feds

    Psychiatric hospital operator Oglethorpe Inc. has agreed to pay $32 million and be excluded from all federal healthcare programs for 10 years to resolve allegations it knowingly failed to return Medicare overpayments in violation of the False Claims Act.

  • May 28, 2026

    McDermott-Led Ampersand Clinches $1.5B Fund

    Healthcare-focused private equity firm Ampersand Capital Partners, advised by McDermott Will & Schulte, on Thursday revealed that it closed its latest fund with $1.5 billion.

  • May 28, 2026

    3 Federal Circuit Clashes To Watch In June

    The Federal Circuit's argument calendar next month includes a dispute between Micron and Netlist over Idaho's law against "bad faith" patent suits, and appeals of multimillion-dollar verdicts against Boston Scientific on a stent patent and TP-Link on Wi-Fi patents.

  • May 28, 2026

    Zoetis Hit With Investor Suit Over Slowed Pet Drug Sales

    Animal health company Zoetis Inc. has been hit with a proposed shareholder class action accusing it of misleading investors about its growth prospects amid rising competition and shifting trends in the veterinary industry.

  • May 28, 2026

    J&J Unit Cleared In Blood Pump Patent Suit In Mass.

    A Massachusetts federal jury on Thursday cleared a Johnson & Johnson MedTech subsidiary of allegations that it infringed a blood pump patent owned by a unit of Swedish medical device company Getinge AB.

  • May 28, 2026

    Chancery Tosses Insider Financing Suit Against Ayala Brass

    The Delaware Chancery Court has dismissed a stockholder derivative suit against several venture capital investors and directors of biotechnology company Ayala Pharmaceuticals Inc., ruling that the plaintiff failed to show the board could not independently evaluate litigation over a disputed 2023 financing deal.

  • May 28, 2026

    Abbott Labs Settles Ill. Genetic Privacy Suit

    Abbott Laboratories has inked a settlement with a proposed class of workers alleging the company's onboarding materials asked for employees' medical history in violation of an Illinois law aimed at protecting residents' genetic information, prompting an Illinois federal judge to dismiss the case Thursday.

  • May 28, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Tennessee became the latest state to approve a policy paving the way for more research into ibogaine; Vermont lawmakers brought a bill doubling cannabis potency and possession limits closer to the finish line; and California legislators approved a bill banning the sale of "laughing gas" used for recreational purposes. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • May 28, 2026

    Husch Blackwell Adds Manatt Healthcare Duo In LA

    Husch Blackwell LLP announced that a pair of Los Angeles-based commercial litigators from Manatt Phelps & Phillips LLP have joined the firm as part of its focus on expanding its California healthcare capabilities.

  • May 28, 2026

    Ex-Reebok CEO Says Biotech Investor Suit Was Shakedown

    Former Reebok CEO and billionaire philanthropist Paul Fireman said a "baseless" shareholder lawsuit against him and a biotech company he later sold to Janssen Pharmaceuticals Inc. for $85 million was an effort to get him to "cave" to demands for more money, according to a complaint filed in Massachusetts state court Wednesday.

  • May 28, 2026

    9th Circ. Won't Revisit FCA Ruling Over Drug Price Program

    The Ninth Circuit has said it will not disturb its March ruling allowing a hospital chain to pursue a False Claims Act lawsuit against various pharmaceutical companies for allegedly causing the government to overpay for drugs under a discount program.

  • May 28, 2026

    Split Fed. Circ. Says $452M Trade Secret Case Was Untimely

    A split Federal Circuit panel on Thursday erased Insulet Corp.'s trade secret victory against EOFlow Co. Ltd., holding that the medical device maker filed its claims too late and reversing a $452 million jury verdict that was later reduced to $59.4 million.

  • May 27, 2026

    Pharmacies Beat Fla. Hospitals' Opioids Suit

    A Florida state judge has handed Walmart, Walgreens and CVS a win in a fight with hospitals over treatment of opioid-addicted patients, finding the hospitals cannot recover damages under state racketeering law because their injuries are indirect.

  • May 27, 2026

    Inovio Brass Hit With Suit Over FDA Approval Claims

    Executives and directors of Inovio Pharmaceuticals Inc. on Wednesday were slapped with a shareholder derivative suit accusing them of damaging the company with misleading statements regarding the likelihood that the U.S. Food and Drug Administration would grant priority review to its DNA medicine.

  • May 27, 2026

    3 Generic Drug Antitrust Deals Totaling $17.9M Get Final Nod

    A Connecticut federal judge on Wednesday gave final approval to a $17.9 million generic drug price-fixing settlement between pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc., and Lannett Co. Inc. and 48 states, territories, and governments, finding the terms reasonable despite an objection.

  • May 27, 2026

    ProPublica Denied Access To Ranbaxy Antitrust MDL Docs

    A Massachusetts federal court denied ProPublica's bid to unseal court filings in settled multidistrict litigation alleging a subsidiary of Indian drugmaker Sun Pharmaceuticals illegally delayed market entry of generic drugs, ruling the nonprofit news organization's request came too late in the case.

  • May 27, 2026

    Pharmacies Hit With Injunction In Gilead Counterfeit Drug Row

    A New York federal judge has issued a preliminary injunction blocking a pair of Queens pharmacies from selling any human immunodeficiency virus medications that bear the Gilead name or the name of two of its products.

  • May 27, 2026

    NJ Justices Revive Eye Injury Suit For 'Gatekeeping' Test

    The Supreme Court of New Jersey revived a woman's suit alleging she suffered serious eye injuries because of a defect in Allergan USA Inc.'s product Ozurdex, ruling Wednesday that the trial court failed to conduct the gatekeeping inquiry required when there is a dispute over the reliability of expert testimony.

  • May 27, 2026

    Stock Trade Co. Wants Out Of Mallinckrodt Clawback Suit

    A high-frequency stock trading firm is asking a Delaware bankruptcy judge to make it the latest defendant dismissed from a bid by Mallinckrodt PLC to recover $1.6 billion paid for stock buybacks before the opioid distributor's bankruptcy.

  • May 27, 2026

    Squires Institutes 3 IPRs, Refuses Case With Limited Impact

    U.S. Patent and Trademark Office Director John Squires granted three petitions for inter partes review in his newest bulk order and broke down why he previously rejected CyberSecure IPS LLC's challenge to a Network Integrity Systems Inc. optical fibers monitoring patent.

  • May 27, 2026

    Squires Says Sun PGR Petition Denied For Not Naming Parent

    Sun Pharmaceutical Industries Inc.'s failure to name its parent company in its challenge to a Biofrontera Inc. patent was why its request for review was rejected early, U.S. Patent and Trademark Office Director John Squires has said.

  • May 27, 2026

    Pierce Atwood Rips Billionaire's 'Absurd' Suit Over Asset Sale

    Pierce Atwood and two attorneys urged a Massachusetts federal judge to reject a Ukrainian billionaire's suit blaming them for a $1.8 million damages order in investor litigation over the billionaire's failed biotech company, saying his own wrongdoing led to the judgment.

  • May 26, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week handled a broad mix of cross-border corporate control disputes, merger settlements, startup equity fights, advancement claims and board oversight litigation, while also weighing fallout from high-profile deals involving Microsoft Corp., The Boeing Co. and Nikola Corp.

  • May 26, 2026

    9th Circ. Backs Reinstating DEI Grants Nixed By Trump

    The Ninth Circuit on Tuesday partially upheld a lower court's preliminary injunction and class certification orders in litigation from University of California researchers against President Donald Trump, backing the reinstatement of grants terminated due to presidential orders against diversity, equity and inclusion initiatives while reversing the injunction for those grants that were rescinded without explanation.

Expert Analysis

  • When Trade Secret Litigation And Criminal Law Collide

    Author Photo

    An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.